CTOs on the Move

Stemtech Healthsciences

www.stemtechbiz.com

 
Stemtech Healthsciences is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Trinity Home Care Products

Trinity Home Care Products is a Rock Island, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spokane Mental health

Since 1970, Spokane Mental Health, a not-for-profit organization, has served children, families, adults and elders throughout Spokane County.

Physicians Academy for Clinical and Management Excellence

Physicians Academy for Clinical and Management Excellence is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NTDA

NTDA is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. NTDA is based in York, PA. You can find more information on NTDA at www.ntda.com

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.